12
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Marked deterioration in the quality of life of patients with idiopathic pulmonary fibrosis during the last two years of life

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background

          Idiopathic pulmonary fibrosis (IPF) is a chronic disease with a high symptom burden and poor survival that influences patients’ health-related quality of life (HRQOL). We aimed to evaluate IPF patients’ symptoms and HRQOL in a well-documented clinical cohort during their last two years of life.

          Methods

          In April 2015, we sent the Modified Medical Research Council Dyspnea Scale (MMRC), the modified Edmonton Symptom Assessment Scale (ESAS) and a self-rating HRQOL questionnaire (RAND-36) to 300 IPF patients, of which 247 (82%) responded. Thereafter, follow-up questionnaires were sent every six months for two years.

          Results

          Ninety-two patients died by August 2017. Among these patients, HRQOL was found to be considerably low already two years before death. The most prominent declines in HRQOL occurred in physical function, vitality, emotional role and social functioning ( p < 0.001). The proportion of patients with MMRC scores ≥3 increased near death. Breathlessness and fatigue were the most severe symptoms. Symptom severity for the following symptoms increased significantly and reached the highest mean scores during the last six months of life (numeric rating scale/standard deviation): breathlessness (7.1/2.8), tiredness (7.0/2.3), dry mouth (6.0/3.0), cough (5.8/2.9), and pain with movement (5.0/3.5).

          Conclusions

          To our knowledge this is the first study demonstrating, that IPF patients experience remarkably low HRQOL already two years before death, especially regarding physical role. In addition, they suffer from severe breathlessness and fatigue. Furthermore, physical, social and emotional wellbeing deteriorate, and symptom burden increases near death. Regular symptom and HRQOL measurements are essential to assess palliative care needs in patients with IPF.

          Electronic supplementary material

          The online version of this article (10.1186/s12890-018-0738-x) contains supplementary material, which is available to authorized users.

          Related collections

          Most cited references38

          • Record: found
          • Abstract: found
          • Article: not found

          Early Versus Delayed Initiation of Concurrent Palliative Oncology Care: Patient Outcomes in the ENABLE III Randomized Controlled Trial.

          Randomized controlled trials have supported integrated oncology and palliative care (PC); however, optimal timing has not been evaluated. We investigated the effect of early versus delayed PC on quality of life (QOL), symptom impact, mood, 1-year survival, and resource use.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            The RAND-36 measure of health-related quality of life.

            The RAND-36 is perhaps the most widely used health-related quality of life (HRQoL) survey instrument in the world today. It is comprised of 36 items that assess eight health concepts: physical functioning, role limitations caused by physical health problems, role limitations caused by emotional problems, social functioning, emotional well-being, energy/fatigue, pain, and general health perceptions. Physical and mental health summary scores are also derived from the eight RAND-36 scales. This paper provides example applications of the RAND-36 cross-sectionally and longitudinally, provides information on what a clinically important difference is for the RAND-36 scales, and provides guidance for summarizing the RAND-36 in a single number. The paper also discusses the availability of the RAND-36 in multiple languages and summarizes changes that are incorporated in the latest version of the survey.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found
              Is Open Access

              Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.

              The Phase II TOMORROW trial and two Phase III INPULSIS(®) trials investigated the efficacy and safety of nintedanib versus placebo in patients with idiopathic pulmonary fibrosis (IPF). To obtain an overall estimate of the treatment effect of nintedanib 150 mg twice daily (bid), pooled and meta-analyses of data from these three trials were conducted.
                Bookmark

                Author and article information

                Contributors
                kaisa.rajala@fimnet.fi
                juho.lehto@uta.fi
                eva.sutinen@helsinki.fi
                hannu.kautiainen@medcare.fi
                marjukka.myllarniemi@helsinki.fi
                tiina.saarto@hus.fi
                Journal
                BMC Pulm Med
                BMC Pulm Med
                BMC Pulmonary Medicine
                BioMed Central (London )
                1471-2466
                20 November 2018
                20 November 2018
                2018
                : 18
                : 172
                Affiliations
                [1 ]ISNI 0000 0000 9950 5666, GRID grid.15485.3d, Department of Palliative Care, Comprehensive Cancer Center,, , Helsinki University Hospital, ; Paciuksenkatu 21, Po BOX 180, FI-00290 Helsinki, Finland
                [2 ]ISNI 0000 0004 0410 2071, GRID grid.7737.4, Faculty of Medicine, , University of Helsinki, ; Helsinki, Finland
                [3 ]ISNI 0000 0001 2314 6254, GRID grid.5509.9, Department of Oncology, Palliative Care Unit, , Tampere University Hospital and Faculty of Medicine and Life Sciences, University of Tampere, ; Tampere, Finland
                [4 ]ISNI 0000 0004 0410 2071, GRID grid.7737.4, Faculty of Medicine, , University of Helsinki, ; Helsinki, Finland
                [5 ]ISNI 0000 0004 0628 207X, GRID grid.410705.7, Primary Health Care Unit, Kuopio University Hospital, Finland and Folkhälsan Research Center, ; Helsinki, Finland
                [6 ]ISNI 0000 0004 0410 2071, GRID grid.7737.4, University of Helsinki and Helsinki University Hospital, Heart and Lung Center, Department of Pulmonary Medicine, ; Helsinki, Finland
                [7 ]ISNI 0000 0004 0410 2071, GRID grid.7737.4, Helsinki University Hospital, Comprehensive Cancer Center, , Department of Palliative Care and Faculty of Medicine, University of Helsinki, ; Helsinki, Finland
                Author information
                http://orcid.org/0000-0001-6198-3627
                Article
                738
                10.1186/s12890-018-0738-x
                6247520
                30458739
                aef7f60d-3aae-4f9f-ba8d-75411a5aa30a
                © The Author(s). 2018

                Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License ( http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

                History
                : 10 July 2018
                : 8 November 2018
                Funding
                Funded by: The Academy of Finland
                Funded by: Sigrid Juselius Foundation
                Funded by: Finnish Anti-Tuberculosis Association
                Funded by: Governmental subsidy for health sciences
                Funded by: Helsinki University Hospital Comprehensive Cancer Center
                Funded by: Väinö and Laina Kivi foundation
                Categories
                Research Article
                Custom metadata
                © The Author(s) 2018

                Respiratory medicine
                idiopathic pulmonary fibrosis,palliative care,health related quality of life,symptoms

                Comments

                Comment on this article